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Abstract
Breast cancer (BC) is the most common newly diagnosed cancer among 
women in Trinidad and Tobago (TT) and BC mortality rates are among the 
highest in the world. Globally, racial/ethnic trends in BC incidence, mortality 
and survival have been reported. However, such investigations have not been 
conducted in TT, which has been noted for its rich diversity. In this study, 
we investigated associations among ancestry, geography and BC incidence, 
mortality and survival in TT. Data on 3767 incident BC cases, reported to 
the National Cancer Registry of TT, from 1995 to 2007, were analyzed in 
this study. Women of African ancestry had significantly higher BC incidence 
and mortality rates (Incidence: 66.96; Mortality: 30.82 per 100,000) compared 
to women of East Indian (Incidence: 41.04, Mortality: 14.19 per 100,000) or 
mixed ancestry (Incidence: 36.72, Mortality: 13.80 per 100,000). Geographi-
cally, women residing in the North West Regional Health Authority (RHA) 
catchment area followed by the North Central RHA exhibited the highest 
incidence and mortality rates. Notable  ancestral differences in survival were 
also observed. Women of East Indian and mixed ancestry experienced sig-
nificantly longer survival than those of African ancestry. Differences in survival 
by geography were not observed. In TT, ancestry and geographical residence 
seem to be strong predictors of BC incidence and mortality rates. Addition-
ally, disparities in survival by ancestry were found. These data should be 
considered in the design and implementation of strategies to reduce BC in-
cidence and mortality rates in TT.
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Introduction
As the most commonly diagnosed malignancy among 
women worldwide, breast cancer (BC) is clearly a major 
global health concern. The most recent data from the 
International Agency for Research on Cancer (IARC) 
 estimated that 1.67 million incident BC cases were diagnosed 
in 2012 [1]. While age- standardized incidence rates vary 
extensively, approximately 53% of all incident BC cases 
occurred in economically developing countries. Globally, 
BC is the fifth most common cause of cancer mortality; 
whereas, in developed countries, it is the second leading 
cause of mortality among women, in economically 
 developing countries this malignancy is the most prevalent 
cause of cancer mortality [1].
The vast majority of studies to date have focused on 
BC in developed countries, where incidence and mortality 
rates have demonstrated a decreasing trend (or at least 
remaining stable in many countries). In contrast, studies 
are limited among many developing countries, where 
 incidence and mortality are projected to continually in-
crease in the next few decades [2–5]. This is particularly 
pronounced in developing countries of the Caribbean 
where population growth, aging, increasing life expectancy 
[5], and the adoption of “westernized” lifestyles, are 
identified as possible contributing factors to the increas-
ing incidence [3, 6, 7]. Furthermore, lack of access to 
adequate comprehensive breast care, including mam-
mography and timely, appropriate treatment and follow-
 up care, may contribute to increases in BC mortality 
[8, 9].
One such country is the English- speaking Republic of 
Trinidad and Tobago (TT) situated in the Southern 
Caribbean (just northeast of Venezuela). Designated by 
the World Bank [10] as a high- income economy, given 
that it has a gross national income (GNI) of ≥$12,746, 
TT has not reached the final stage of development. 
Nonetheless, TT is the most industrialized of all Caribbean 
nations, with oil, natural gas, chemical industries, and 
food and beverage industries, and has recently experienced 
an 8% economic growth, more than double the regional 
average [11]. As of 2011 [12], TT had a population of 
1,328,019, with diverse self- reported ancestries, including 
East Indian (35%), African (34%), mixed (23%; [African/
East Indian, 8% and mixed/other, 15%]), other (<1%), 
and unknown ancestries (6%) [12].
The Ministry of Health is the national authority 
 responsible for oversight of the national healthcare system. 
There are five Regional Health Authorities (RHAs) that 
are responsible for the provision of healthcare services in 
their respective geographic catchment area. Cancer screen-
ing and treatment services are provided free to all citizens 
of TT at six public medical facilities. Furthermore, the 
Chronic Disease Assistance Programme provides free 
 oncology prescription drugs.
Despite the opportunities afforded by universal health-
care in TT, BC mortality rates are among the highest in 
the Caribbean and the world [13–16]. A recent study by 
Camacho- Rivera and colleagues [16], indicated that women 
in TT are diagnosed with BC at a later stage and initiate/
receive multi- mode therapy (i.e., combination of ≥2 types 
of treatment) for their disease at very low levels [16]. 
Utilizing data from the National Cancer Registry of TT, 
on incident BC cases diagnosed between January 1995 
and December 2007, we sought to expand upon the find-
ings of Camacho- Rivera and colleagues [16], with the 
objective of investigating associations among ancestry, 
geography and BC incidence, mortality and survival in 
TT. Findings from this study will be integral to under-
standing some of the factors associated with the poor 
outcomes observed among BC patients in TT.
Materials and Methods
Study design and measures
This study included incident, invasive BC cases among 
female patients reported to the National Cancer Registry 
of TT. Prospectively collected tumor incidence and mor-
tality data from January 1, 1995 and December 31, 2007 
were included in the analysis. The population- based cancer 
registry was established in 1994 by the Trinidad and 
Tobago Cancer Society, using cancer registry guidelines 
set by IARC [17, 18]. This registry uses the CANREG 
database and statistical software (Version 4.33). Records 
from both public and private biomedical institutions 
populated the registry dataset. Public sector institutions 
included Port of Spain General Hospital, Caura Hospital, 
National Radiotherapy Center, Sangre Grande Hospital, 
Tobago Regional Hospital, Mount Hope Women’s 
Hospital, Eric Williams Medical Sciences Complex, San 
Fernando Hospital, Point Fortin Area Hospital, and the 
Central Statistical Office. Private sector data sources in-
cluded Augustus Long Hospital, Petrotrin- Santa Flora 
Medical Centre, Community Hospital of the Seven Day 
Adventists, Brian Lara Treatment Centre, and Westshore 
Private Hospital.
In Trinidad, there is a local government system with 
five Municipal Corporations for the cities of Port of Spain 
and San Fernando, and the boroughs of Arima, Point 
Fortin and Chaguanas, as well as nine Regional 
Corporations (including those of: (1) Couva, Tabaquite, 
and Talparo; (2) Diego Martin; (3) Mayaro and Rio Claro; 
(4) Penal and Debe; (5) Princes Town; (6) Sangre Grande; 
(7) San Juan and Laventille; (8) Siparia; and (9) Tunapuna 
and Piarco) (Fig. 1). Tobago is administratively controlled 
1744 © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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by the Tobago House of Assembly. The geographical area 
of residence data from the cancer registry was aligned 
with the corresponding Ministry of Health RHAs, which 
provides healthcare personnel and facilities for persons 
residing in the catchment area. The North West Regional 
Health Authority (NWRHA); North Central Regional 
Health Authority (NCRHA); South West Regional Health 
Authority (SWRHA); Eastern Regional Health Authority 
(ERHA) and Tobago Regional Health Authority (TRHA) 
are responsible for direct provision of healthcare services 
in their respective catchment area. However, there are 
specialized cancer centers in various RHAs that can be 
accessed with a doctor’s referral without regard to the 
patient’s place of residence.
In the registry data file, demographic characteristics (age 
at diagnosis and ancestry) were self- reported. Four ancestry 
groups are most prevalent among the population of TT: 
African, East Indian, mixed, and other. Imputation was 
used to ascribe ancestry among cancer cases with unknown/
missing ancestry (n = 5301 [21.2%]) [19]. Essentially, 
four separate predictive binary logistic regression models 
were calculated. Ancestry was used as the dependent vari-
able for estimation purposes. Known demographic variables 
including: gender, age, and residence (15 corporations and 
boroughs used as dummy variables) were used as inde-
pendent variables in the four predictive regression models 
to assign ancestry based on known profiles from all  instances 
of self- reporting data. After fitting the four models for 
the cases with missing ancestry data, probabilities of 
 predicted values of ancestry were calculated. These values 
revealed the probability of each cancer patient’s placement 
into each of the four ancestry groups. Cancer patients 
with missing ancestry were then assigned to one of the 
four ancestry groups according to the highest probability 
Figure 1. Geospatial maps of breast cancer incidents and mortality rates in Trinidad and Tobago 1995–2007: (A–B) age- standardized rates for all 




1745© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
 
Breast Cancer Disparities in Trinidad and TobagoW. A. Warner et al.
of being a member of that group. Using this method, all 
of the cases with unknown/missing ancestry were assigned 
to either the African or East Indian ancestry group as 
the other probabilities were significantly lower and would 
have increased the errors of estimation.
Clinical data (stage, grade, histology, and treatment 
modalities) were classified based on WHO International 
Classification of Disease (ICD- O- 3) codes. Female BC cases 
with missing data and/or data errors (e.g., date of death 
before date of incident BC, no date of last follow- up, etc.) 
were excluded (n = 10). The analytic dataset consisted of 
3767 incident invasive BC cases. This study received  approval 
by Institutional Review Boards of all participating 
institutions.
Statistical analysis
Study sample characteristics overall and indexed by an-
cestry were described using frequencies and proportions. 
Chi- square and Fisher’s exact tests were used to compare 
sample characteristics by ancestry. Crude incidence and 
mortality rates in TT were estimated using population 
data from the TT 2000 and 2010 census [12]. From these 
estimates, we calculated the age- standardized incidence 
and mortality rates (per 100,000) based on the world- 
standardized population weights [20], to better compare 
BC rates in TT to global trends. Populations of corpora-
tions in the other years were estimated through interpola-
tion using the “irregular points of year” estimation method 
[17, 18]. Cox proportional hazards models were used to 
calculate the hazard ratios (HR) and 95% confidence 
 intervals (CIs) of BC mortality by ancestry and by geog-
raphy. In the initial model, we adjusted for age at BC 
diagnosis only. In the multivariable- adjusted model, we 
further adjusted for marital status, mode of detection, 
cancer stage, and whether any BC treatment was received. 
All reported P- values are two- sided and P < 0.05 was 
considered statistically significant. Analyses were done us-
ing Statistical Package of Social Science V.20 (SPSS) (IBM 
Corporation, Valhalla, NY) and R Statistical Software (R 
Foundation, Vienna, Austria).
Results
Characteristics of incident BC cases in 
Trinidad and Tobago
Data are reported on 3767 incident primary BC cases (54% 
of African ancestry, 33% of Indian ancestry, and 13% of 
mixed ancestry) reported to the TT cancer registry between 
January 1, 1995 and December 31, 2007. As shown in 
Table 1, overall the mean age at diagnosis was 56 years, 
with significant differences by ancestry. Specifically, women 
of Indian ancestry presented at a younger age, compared 
to women of African ancestry or mixed ancestry (P < 0.01).
In terms of clinical characteristics, localized stage 
(39.93%) was most frequent, followed by regional (33.66%) 
and distant (8.57%) stages, with the highest frequency 
of BC patients diagnosed with localized cancer observed 
among women of Indian ancestry (P < 0.01). Although 
there were substantial ‘unspecified’ data on tumor grade 
(78% overall), women of mixed ancestry were more 
 frequently diagnosed with poorly differentiated tumors 
and least likely to be diagnosed with well- differentiated 
tumors, compared to women of African or Indian ancestry 
(P < 0.01). Histologically, adenocarcinoma or carcinoma, 
not otherwise specified were diagnosed less frequently 
among women of mixed ancestry (32.14%), compared 
to women of Indian (37.24%) or African ancestry (39.26%; 
P < 0.01). There were significant differences in the receipt 
of surgical treatment and initiation of chemotherapy, 
radiation therapy, hormone therapy, and immunotherapy 
by ancestry; specifically, women of African ancestry were 
least likely to have received/initiated any BC treatment 
compared to women of Indian and mixed ancestry (all 
P < 0.01). At the time of last contact (1997–2007), the 
largest proportion of cases still alive were of Indian 
 ancestry (67.58%), followed by those of mixed ancestry 
(64.47%), and lastly, African ancestry (56.49%).
Breast cancer incidence, mortality, and 
survival in Trinidad and Tobago
Overall, women of African ancestry had the highest age- 
standardized BC incidence rates per 100,000, followed 
by women of Indian and mixed ancestry (African ancestry: 
66.96, 95% CI 63.95–65.97; Indian ancestry: 41.04, 95% 
CI 38.75–43.34; and mixed ancestry: 36.72, 95% CI 
33.39–40.03). Women of African ancestry also had the 
highest age- standardized BC mortality rates (30.82 per 
100,000, 95% CI 28.80–32.84), followed by women of 
Indian ancestry (14.19 per 100,000, 95% CI 12.84–15.54) 
and mixed ancestry (13.80 per 100,000, 95% CI 
11.79–15.81).
As shown in Figure 1, BC incidence and mortality rates 
were highest in the NWRHA geographic region. In 
NWRHA, incidence and mortality rates were 53.82 and 
23.52 per 100,000, respectively; the nation’s capital city 
of Port- of- Spain had the highest rates of both incidence 
(75.19 per 100,000) and mortality (36.12 per 100,000). 
In NCRHA, incidence and mortality rates were 45.78 per 
100,000 and 18.72 per 100,000, respectively; the corpora-
tion of Arima had the incidence (66.13 per 100,000) and 
mortality rates (27.34 per 100,000). In TRHA, incidence 
and mortality rates were 43.44 and 19.97 per 100,000; 
the parish of St. David had the highest incidence (58.60 
1746 © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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Table 1. Characteristics of incident breast cancer cases reported to the cancer registry, overall and by ethnicity, Trinidad and Tobago, 1995–2007.
Characteristics
Overall N = 3767  
n (%)
African n = 2020  
n (%)
Indian n = 1246  
n (%)
Mixed n = 501  
n (%) P1
Demographic characteristics
Age at diagnosis (years), 
mean ± SD
56.55 ± 14.63 57.46 ± 15.29 54.29 ± 13.00 58.48 ± 15.10 <0.01
Age at diagnosis (years)
 <45 856 (22.72) 451 (22.33) 307 (24.64) 98 (19.56) <0.01
 45–60 1489 (39.53) 743 (36.78) 544 (43.66) 202 (40.32)
 >60 1422 (37.75) 826 (40.89) 395 (31.70) 201 (40.12)
Marital status
 Divorced/separated/widowed 727 (19.30) 375 (18.56) 240 (19.26) 112 (22.36) <0.01
 Married/living as married 1669 (44.31) 751 (37.18) 693 (55.62) 225 (44.91)
 Single/never married 744 (19.75) 499 (24.70) 133 (10.67) 112 (22.36)
 Unspecified 627 (16.64) 395 (19.55) 180 (14.45) 52 (10.38)
Geographic area of residence2
 Eastern 194 (5.15) 100 (4.95) 68 (5.46) 26 (5.19) <0.01
 North Central 915 (24.29) 457 (22.62) 333 (26.73) 125 (24.95)
 North West 1314 (34.88) 866 (42.87) 195 (15.65) 253 (50.50)
 South West 1175 (31.19) 442 (21.88) 643 (51.61) 90 (17.96)
 Tobago 165 (4.38) 152 (7.52) 6 (0.48) 7 (1.40)
 Unknown 4 (0.11) 3 (0.15) 1 (0.08) 0 (0.00)
Clinical characteristics
Mode of detection
 Clinical diagnosis 1601 (42.5) 849 (42.30) 534 (42.35) 218 (41.52) <0.01
 Incidental finding at autopsy 2 (0.05) 2 (0.10) 0 (0.00) 0 (0.00)
 Unknown/missing 2164 (57.45) 1156 (57.60) 727 (57.65) 281 (56.31)
Stage at diagnosis
 Localized 1504 (39.93) 768 (38.02) 530 (42.54) 206 (41.12) <0.01
 Regional 1268 (33.66) 652 (32.28) 430 (34.51) 186 (37.13)
 Distant 323 (8.57) 202 (10.00) 79 (6.34) 42 (8.38)
 Unknown 672 (17.84) 398 (19.70) 207 (16.61) 67 (13.37)
Grade
 Grade I – Well differentiated 68 (1.81) 37 (1.83) 30 (2.41) 1 (0.20) <0.01
 Grade II – Moderately  
  Differentiated
175 (4.65) 97 (4.80) 56 (4.49) 22 (4.39)
 Grade III – Poorly  
  Differentiated
467 (12.40) 256 (12.67) 127 (10.19) 84 (16.77)
 Grade IV – Undifferentiated 116 (3.08) 49 (2.43) 57 (4.57) 10 (2.00)
 Unspecified 2941 (78.07) 1581 (78.27) 976 (78.33) 384 (76.65)
Histology
 Adenocarcinoma 350 (9.29) 164 (8.12) 158 (12.68) 28 (5.59) <0.01
 Carcinoma NOS 1068 (28.35) 629 (31.14) 306 (24.56) 133 (26.55)
 Other 2349 (62.36) 1227 (60.74) 782 (62.76) 340 (67.86)
Surgical treatment received
 Yes 2778 (73.75) 1404 (69.50) 984 (78.97) 390 (77.84) <0.01
 No 502 (13.33) 311 (15.40 125 (10.03) 66 (13.17)
 Missing 487 (12.92) 305 (15.10) 137 (11.00) 45 (8.99)
Chemotherapy initiated
 Yes 1576 (41.84) 779 (38.56) 567 (45.50) 230 (45.91) <0.01
 No 1699 (45.10) 933 (46.19) 542 (43.50) 224 (44.71)
 Missing 492 (13.16) 308 (15.25) 137 (11.00) 47 (9.38)
Radiation therapy initiated
 Yes 1355 (35.97) 692 (34.26) 433 (34.75) 230 (45.91) <0.01
 No 1259 (33.42) 688 (34.06) 423 (33.95) 148 (29.54)
 Missing 1153 (30.61) 640 (31.68) 390 (31.30) 123 (24.55)
Hormone therapy initiated
 Yes 1282 (34.03) 647 (32.03) 451 (36.20) 184 (36.73) <0.01
 No 1995 (52.96) 1067 (52.82) 658 (52.81) 270 (53.89)
 Missing 490 (13.01) 306 (15.15) 137 (11.00) 47 (9.38)
(Continued)
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per 100,000) and mortality rates (28.00 per 100,000), 
 respectively. In SWRHA, incidence and mortality rates 
were 38.88 and 14.64 per 100,000. In the SWRHA area, 
the corporation of San Fernando had the highest BC 
 incidence (47.12 per 100,000) and Point Fortin demon-
strated the highest mortality rate (21.09 per 100,000). In 
ERHA, incidence and mortality rates were 34.07 and 15.11 
per 100,000; the corporation of Sangre Grande had the 
Characteristics
Overall N = 3767  
n (%)
African n = 2020  
n (%)
Indian n = 1246  
n (%)
Mixed n = 501  
n (%) P1
Immunotherapy initiated
 No 3270 (86.81) 1709 (84.60) 1109 (89.00) 452 (90.22) <0.01
 Missing 494 (13.11) 310 (15.35) 137 (11.00) 47 (9.38)
Vital status at last contact
 Alive 2306 (61.22) 1141 (56.49) 842 (67.58) 323 (64.47) <0.01
 Deceased 1461 (38.78) 879 (43.51) 404 (32.42) 178 (35.53)
NOS, not otherwise specified. Statistically significant (P <0.05) differences are bolded.
1Chi- square or Fisher’s exact tests were used to derive P- values.
2Geographic area of residence was based on residence within the catchment area of the five Regional Health Authorities (RHAs), which are respon-
sible for the provision of healthcare services in Trinidad and Tobago.
Table 1.  Continued.
Table 2. Hazard ratios (HR) and 95% confidence intervals (CI) of mortality in each Regional Health Authority (RHA) catchment area in Trinidad and 
Tobago, 1995–2007.
Mortality NWRHA ERHA NCRHA SWRHA TRHA
Model
 Age- adjusted 1.00 (Ref) 1.06 (0.83–1.34) 0.94 (0.82–1.07) 0.80 (0.70–0.91) 0.98 (0.76–1.26)
 Multivariable- adjusted1 1.00 (Ref) 0.98 (0.77–1.24) 0.86 (0.75–0.98) 0.67 (0.58–0.77) 0.98 (0.76–1.27)
Statistically significant (P <0.05) estimates are bolded.
1Multivariable models adjusted for age at incidence, marital status, detection method, cancer stage, and treatment (yes/no). The model was adjusted 
for initiation of any treatment.
Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) of mortality (B) in each Regional Health Authority (RHA) catchment area in Trinidad and 
Tobago, by ancestry, 1995–2007.
Mortality Indian Mixed African
All RHAs
 Age- adjusted 1.00 (Ref) 0.93 (0.78–1.11) 1.31 (1.17–1.48)
 Multivariable- adjusted1 1.00 (Ref) 0.99 (0.83–1.19) 1.12 (0.99–1.26)
ERHA
 Age- adjusted 1.00 (Ref) 0.48 (0.19–1.17) 0.90 (0.55–1.49)
 Multivariable- adjusted1 1.00 (Ref) 0.89 (0.35–2.25) 1.01 (0.59–1.74)
NCRHA
 Age- adjusted 1.00 (Ref) 1.26 (0.90–1.77) 1.27 (1.00-1.62)
 Multivariable- adjusted1 1.00 (Ref) 1.12 (0.79–1.58) 0.97 (0.75–1.25)
NWRHA
 Age- adjusted 1.00 (Ref) 0.88 (0.65–1.20) 1.46 (1.14–1.87)
 Multivariable- adjusted1 1.00 (Ref) 0.85 (0.63–1.16) 1.20 (0.94–1.55)
SWRHA
 Age- adjusted 1.00 (Ref) 0.74 (0.48–1.15) 1.16 (0.94–1.44)
 Multivariable- adjusted1 1.00 (Ref) 0.98 (0.63–1.53) 0.91 (0.72–1.15)
TRHA
 Age- adjusted 1.00 (Ref) 0.57 (0.09–3.49) 0.67 (0.16–2.79)
 Multivariable- adjusted1 1.00 (Ref) 0.36 (0.05–2.53) 0.49 (0.12–2.12)
Statistically significant (P < 0.05) estimates are bolded.
1Multivariable models adjusted for age at incidence, marital status, detection method, cancer stage, and treatment (yes/no).
1748 © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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highest incidence (35.28 per 100,000) and mortality rates 
(16.41 per 100,000).
Table 2 shows the HRs and CIs of BC mortality by 
geography. After adjustment for age at incidence, marital 
status, detection method, cancer stage, and treatment ini-
tiation, the mortality rates in the NCRHA (HR 0.86, 95% 
CI: 0.75–0.98) and SWRHA (HR 0.67, 95% CI: 0.58–0.77) 
were significantly lower than observed in the NWRHA. 
We further investigated differences in mortality rates in 
each RHA by ancestry (Table 3). Looking within the 
individual RHAs, compared to women of Indian ancestry, 
those of African ancestry had higher mortality rates in 
NCRHA (HR 1.27, 95% CI, 1.00–1.62) and NWRHA (HR 
1.46, 95% CI, 1.14–1.87).
Unadjusted Kaplan–Meier curves indicate that 
BC cases residing in the NWRHA catchment area 
had lowest survival probability (5- year survival, 24%; 
10- year survival, 5%). For women in the other RHAs, the 
5- year survival rate was 30% and the 10- year survival 
rate was <20% (Fig. 2A). Unadjusted Kaplan–Meier 
Figure 2. Breast cancer survival probability by ancestry (A) and by geography (B) based on residence within Regional Health Authority catchment area.
(A)
(B)
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curves showed that the African ancestry was associated 
with the lowest survival probability over 12.5- year 
 follow- up period, whereas women of Indian ancestry 
had the best survival probability up to approximately 
year 7.5 with mixed ancestry having the best survival 
probability beyond that year. The 5- year survival 
rates for patients of African, mixed and Indian ances-
try were 24%, 32%, and 38%, respectively, and the 
 10- year rates were 5%, 5.1%, and 8%, respectively 
(Fig. 2B).
Discussion
Analysis of ancestral and geographic differences in BC 
incidence and mortality rates is an essential component 
of understanding the epidemiologic landscape of BC in 
TT. In this study, we investigated whether disparities 
 existed by ancestry and geography for BC incidence, mor-
tality, and survival in TT for the study period 1995–2007. 
We observed striking differences in these measures by 
ancestry and geography. Most notably, women of African 
ancestry had a BC incidence rate that was twice as high 
as that observed among women of East Indian and mixed 
ancestry. This finding was true in all geographic regions 
of TT. Overall, incidence and mortality rates were highest 
among residents of the NWRHA catchment area, which 
includes the capital city of TT, Port of Spain. Relatedly, 
BC cases residing in this geographic area also exhibited 
the lowest 5- year relative survival.
It is plausible that the highest BC incidence rates were 
observed in the NWRHA geographic area given that the 
majority of the public as well as private institutions of-
fering cancer screening, diagnosis and/or treatment services 
are located in this catchment area including, the TT Cancer 
Society, Port of Spain General Hospital, National 
Radiotherapy Centre, the Brian Lara Cancer Treatment 
Centre of TT, and Pink Hibiscus Breast Health Specialists. 
What may account for the high mortality rates that were 
also observed in this area relates to the fact that between 
1995 and 2007, the National Radiotherapy Center was 
the only public center offering adjuvant and palliative 
care, which we hypothesize would have reduced access 
to timely treatment among some BC patients. This merits 
further study to understand such factors as preventive 
care, outreach efforts, medical interventions, in particular 
genomic (personalized) medical treatments, and resource 
allocation throughout the nation.
In the United States (U.S.), minority women, particu-
larly women of African descent, although having lower 
overall BC incidence, are more likely than their white 
counterparts to die from their disease, even after ac-
counting for later stage at diagnosis [21–23]. In contrast, 
what we have observed among BC cases in TT is that 
both incidence and mortality rates were highest among 
women of African descent. Similar findings were observed 
by Dindyal et al. [24], who analyzed data from the Port 
of Spain region of TT specifically and found that the 
largest proportion of BC was diagnosed among women 
of African descent (54%) followed by women of Indian 
descent (35%) and mixed ancestry (11%). Some studies 
have suggested that differences in BC incidence and mor-
tality are related to factors related to socioeconomic status 
and/or inequity in healthcare access and utilization [25–
29]. While this may be true in the U.S., access to care 
is likely not a major concern in TT, given the equal 
access to healthcare model in place in the nation. However, 
it is quite possible that intrinsic biological variation in 
BC exists by ancestry or differences in the distribution 
of etiological factors by ancestry may explain some of 
the observed disparities in TT [30, 31]. In addition, BC 
among women of African ancestry tends to have more 
aggressive features [2, 21, 32]. It is unknown whether 
this association exists among women in TT, therefore 
warranting further study.
The TT cancer registry database captured information 
on systemic therapies delivered to BC patients, however 
there was no clinical annotation containing hormone 
 receptor expression status, BC subtype information, or 
indication as to whether BC treatment was administered 
in the adjuvant setting. A recent study examining BC 
treatment and outcomes in TT reported that >50% of 
BCs diagnosed between 1995 and 2005 were approximated 
to hormone receptor negativity, using receipt of hormone 
therapy as a surrogate [16]. Intrinsic subtyping of BC 
patients at the time of diagnosis is not routinely done 
in TT. It may be that a high prevalence of BCs with 
more aggressive features (e.g., hormone receptor negativity, 
later stage, higher grade) may contribute to the high 
mortality and poor survival rates observed in TT [33, 
34]. Given that BC is a heterogeneous disease, it is critical 
that molecular subtyping be prioritized in TT as this will 
allow for improved patient prognostication and stratifica-
tion, and personalized treatment [22, 33, 35, 36].
In many higher income countries, there has been a 
documented decline or leveling off of BC incidence rates 
[37]. In the data from TT, however, we observed an 
increase across all demographic groups. These findings 
imply a need to improve cancer prevention, screening, 
and treatment options, as well as genetics and genomics- 
based research. In higher income countries, there is an 
increasing shift toward precision medicine, where the 
mutational landscape is evaluated to determine the biology 
of the tumor, risk of recurrence, and the most appropri-
ate treatment protocol [37]. TT will need to develop a 
core genetics and genomics- sequencing infrastructure to 
address the local genomic complexity of cancer.
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Our finding of older age at diagnosis among women 
of African ancestry suggests that there might be underly-
ing molecular mechanisms playing a central role. This is 
consistent with data from Raju et al. [38], which indicated 
that carcinoma was observed in only 1.1% of all breast 
biopsies among women ≤30 years. Still, almost one- quarter 
of incident BCs (22.72%) in this study were diagnosed 
at <45 years. It is well established that germline muta-
tions in BC susceptibility genes such as BRCA1, BRCA2, 
CHEK2, and TP53 have founder effects leading to increased 
risk for cancer incidence and mortality [39–45], particularly 
among younger women. Interestingly, there has also been 
a documented increase in BC mortality over the past few 
decades in TT. Naraynsingh and colleagues[46] showed 
that between 1970 and 2004, age- standardized BC mortal-
ity had increased from 14.9 per 100,000 to 24.4 per 100,000, 
with an increase observed among women <50 years as 
well as those ≥50 years. Among women <50 years, mor-
tality rates increased from 3.8 per 100,000 in 1970 to 9.2 
per 100,000 in 2004, whereas among women ≥50 years 
it increased from 48.6 per 100,000 to 99.4 per 100,000 
during the same time period. The high mortality rates, 
which are clearly increasing in TT [46], and the observed 
disparities by ancestry reported herein suggest that genomic 
assessment of the mutational spectra as well as genetic 
ancestry analysis is warranted in TT. This is an ideal 
environment to examine associations between genetics, 
incidence, and disease aggressiveness since there are fewer 
disparate mitigating factors.
The observed differences in BC incidence and mortality 
by geography may be an indication that differential spatial 
access to timely and appropriate care might impact cancer 
diagnosis, prognosis, and mortality rates in this Caribbean 
setting. Although there is universal healthcare coverage 
in TT, patients are required to obtain referrals from a 
physician prior to accessing treatment [47]. While there 
are no geographic boundaries in TT per se that limit 
access to the public medical facilities that provide cancer 
care and at minimum, one hospital and several clinics 
are located within each RHA catchment area, there are 
only four licensed oncologists (none in Tobago) serving 
the entire population [48]. Furthermore, the estimated 
travel time in TT to an oncology center is between 0.5 
and 9 h with <1 h for 26.6% of the population versus 
in the U.S. (e.g.,) where it is <1 h for 92% of the popu-
lation [49]. This might be a major contributing factor to 
the geographic disparities. Numerous studies report an 
inverse association between travel time and cancer care 
[50–55]. However, in TT the highest incidence and mor-
tality rates are in areas closest to cancer centers. Further 
examination of the association between spatial access, 
distance- and travel time to cancer care facilities, and BC 
outcomes in TT is needed.
This study has some limitations that should be con-
sidered in the interpretation of our findings. First, there 
were missing data, particularly related to patients’ ancestry, 
which highlights the need for more thorough data col-
lection by cancer registry. Another consideration is that 
this study was based on retrospective analysis of an anony-
mous dataset; there was no way to supplement any missing 
data. Another limitation of this study was that we did 
not evaluate BC screening patterns. Therefore, the observed 
disparities in mortality may be due to disparities in screen-
ing and possibly treatment, which may be dependent upon 
a patient’s place of residence, differences in resource al-
location by RHAs and the overall cancer care received. 
As a result of this, we cannot verify that cancer patients 
seek cancer care at medical centers within their region 
of residence, which is another limitation of this study. 
Patient demographic information was self- reported and 
may not reflect the entire picture. In particular, ancestry 
was self- reported, without the benefit of genomic screen-
ing for admixture markers. The absence of data on 
 reproductive BC risk factors (e.g., age at first birth, and 
body mass index (BMI) was also a limitation. The 
 association between BMI and BC mortality is well estab-
lished and studies have shown significantly higher BMI 
among women of African ancestry, compared to other 
racial/ethnic groups [56], which could have contributed 
to the differences in BC mortality and survival by ancestry 
observed in this study.
Despite limitations, this work has important implica-
tions. This study is the first to examine associations among 
ancestry, geography, and BC incidence, mortality, and 
survival in Trinidad and Tobago. The importance of this 
work is underscored by the fact that the BC incidence 
and mortality rates are among the highest in the Caribbean 
[13–15, 57] and the world even though [1–3] TT has 
the largest healthcare budget in the Caribbean. In low- 
and middle- income countries, 18% of BC cases are 
 attributable to modifiable causes such as alcohol intake, 
physical inactivity, and postmenopausal overweight and 
obesity [58]. Hence, prevention activities, which incorpo-
rate the adoption of a healthier lifestyle, including diet, 
could impact BC incidence in TT. Nevertheless, early 
detection to improve survival might have the greatest 
impact in BC control in TT and efforts to promote such 
endeavors are needed. This study also provides an ancestral 
and geographical context from which resource allocation 
decisions can be made. The findings presented here high-
light the need for similar studies in the other Caribbean 
island nations. In addition, this study highlights the need 
for targeted outreach efforts by ancestry and geography 
so as to reduce the documented disparities. Given the 
size of Trinidad and Tobago, the disparities reported herein 
suggest a need for genetic/genomic studies to determine 
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whether these are ancestry- based genomic alterations driv-
ing incidence, mortality, and treatment resistance. This 
study also highlights the need for research to understand 
why the highest rates of incidence and mortality are in 
close proximity to cancer centers and biomedical institu-
tions, given that TT has an equal access to care model.
In conclusion, we present evidence that there are 
 associations between ancestry, geography, and BC incidence, 
mortality, and survival in TT. Medical interventions that 
seek to improve oncology services nationally will fail to 
narrow these disparities since there might exist population- 
level social inequalities, and genomic differences, which 
can contribute to our findings. Our findings indicate a 
need for a national dialog on these disparities and the 
deployment of equal access and utilization of quality cancer 
care, early detection, genetics and genomics research, 
 molecular BC subtyping, targeted outreach, and improved 
therapeutics to reduce BC disparities.
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